Have you been paying attention to shares of Veeva Systems (VEEV) ? Shares have been on the move with the stock up 16.8% over the past month. The stock hit a new 52-week high of $291.69 in the previous session. Veeva Systems has gained 34.2% since the start of the year compared to the -1.5% move for the Zacks Medical sector and the 27.2% return for the Zacks Medical Info Systems industry.What's Driving the Outperformance?The stock has a great record of positive earnings surprises, as it hasn't missed our ear ...

Group 1 - The stock of Inspire Medical Systems, Inc. (INSP) is experiencing significant attention due to high implied volatility in the options market, particularly for the Jan. 16, 2026 $95 Call option [1] - Implied volatility indicates the market's expectation of future price movement, suggesting that investors anticipate a significant change in the stock's price, potentially due to an upcoming event [2] - Inspire Medical Systems holds a Zacks Rank 3 (Hold) in the Medical Info Systems industry, which is in the top 33% of the Zacks Industry Rank, but analysts have lowered earnings estimates for the current quarter from 41 cents per share to 22 cents [3] Group 2 - The high implied volatility for Inspire Medical Systems may indicate a developing trading opportunity, as options traders often seek to sell premium on options with high implied volatility to capture decay [4]

Company Performance - Hims & Hers Health, Inc. (HIMS) closed at $55.25, reflecting a -2.83% change from the previous day, underperforming the S&P 500's 0.55% gain [1] - Over the past month, HIMS shares have increased by 2.99%, while the Medical sector and S&P 500 gained 3.49% and 6.29%, respectively [1] Upcoming Financial Results - The upcoming EPS for Hims & Hers is projected at $0.17, indicating a significant 183.33% increase compared to the same quarter last year [2] - Quarterly revenue is expected to reach $551.84 million, up 74.83% from the previous year [2] Fiscal Year Projections - For the entire fiscal year, earnings are projected at $0.73 per share, representing a 170.37% increase from the prior year [3] - Revenue for the fiscal year is estimated at $2.34 billion, reflecting a 58.31% increase from the previous year [3] Analyst Estimates and Outlook - Recent adjustments to analyst estimates indicate a favorable outlook on the company's business health and profitability [4] - The Zacks Consensus EPS estimate has increased by 5.66% over the past month, with Hims & Hers currently holding a Zacks Rank of 2 (Buy) [6] Valuation Metrics - Hims & Hers is currently trading at a Forward P/E ratio of 77.39, which is a premium compared to the industry average of 27.09 [7] - The company's PEG ratio stands at 2.12, aligning with the industry average [7] Industry Context - The Medical Info Systems industry, part of the Medical sector, has a Zacks Industry Rank of 70, placing it in the top 29% of over 250 industries [8] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [8]

Core Insights - Tempus AI (TEM) experienced a 12.5% surge in early June, significantly outperforming the broader market due to positive investor reactions to new product launches [1][9] - The company has established a $200 million partnership with AstraZeneca and Pathos to develop a large oncology-focused foundation model, enhancing its position in AI-driven drug discovery [5][9] - Despite revenue growth, Tempus remains unprofitable, reporting an adjusted EBITDA loss of $16.2 million in Q1 2025, although this is an improvement from the previous year [14][16] Strategic Product Innovation - The xM Liquid Biopsy Assay utilizes whole-genome sequencing and fragmentomics for noninvasive monitoring of immunotherapy responses in advanced cancer patients, providing real-time treatment insights [3] - Tempus One, an AI-powered clinical assistant, has been integrated into major EHR systems, offering real-time, patient-specific insights to enhance clinical decision-making [4] Financial Performance - Year-to-date, TEM stock has increased by 83.8%, outperforming the Medical Info Systems industry and the S&P 500 [7] - The stock is currently trading at a forward 12-month price-to-sales (P/S) ratio of 7.77, which is above the industry average of 6.09, indicating it may be overvalued compared to peers [15][16] Recent Developments - The acquisition of Deep 6 AI enhances Tempus's clinical trial matching and provider analytics capabilities, expanding its provider connectivity to over 4,000 connections [6] - The partnership with AstraZeneca is expected to leverage over 300 petabytes of data, aiming to accelerate AI-driven drug discovery and diagnostics [5]

Core Viewpoint - Tempus AI and Butterfly Network are two AI-driven healthcare companies that are transforming diagnostics through their innovative approaches, with Tempus focusing on precision oncology and Butterfly on point-of-care imaging [1] Company Performance - Tempus AI's shares have increased by 55.4% over the past year, while Butterfly Network's shares have surged by 114.8%, significantly outperforming the Medical Info Systems industry's gain of 13.6% and the S&P 500's rise of 10.8% [2] Tempus AI Highlights - Revenue Growth and Margin Expansion: Tempus AI reported a 75.4% year-over-year revenue increase in Q1 2025, with its data licensing segment growing by 58%, contributing to overall profitability [6][8] - Positive EBITDA Outlook: The company is on track to achieve adjusted EBITDA profitability in 2025, narrowing its adjusted EBITDA loss to $16.2 million from $43.9 million a year earlier, reflecting strong revenue growth and disciplined spending [7] - Strategic Partnerships and Contract Backlog: Tempus AI secured a $200 million deal with AstraZeneca and Pathos, alongside a remaining contract value of over $1 billion, ensuring predictable revenues and financial stability [8][9] Butterfly Network Highlights - Strong Financial Performance: Butterfly Network achieved 20% year-over-year revenue growth in Q1 2025, with gross margins rising to 63% and adjusted EBITDA loss narrowing to $9.1 million [10] - Diversified Product Portfolio: The company has expanded its offerings under CEO Joseph DeVivo, introducing multiple probes and the Butterfly Garden AI marketplace, which diversifies revenue streams [11] - International Growth: Despite challenges, Butterfly Network's international revenues grew by 9% year-over-year, supported by pricing gains and partnerships with over 800 NGOs [12] Valuation Comparison - Tempus AI has a forward price-to-sales (P/S) ratio of 7.90, while Butterfly Network's ratio is 5.00, indicating that Butterfly is attractively valued compared to the industry average of 5.51 [13] - Analysts suggest a 10.55% upside for Tempus AI based on price targets, while Butterfly Network's average target indicates a potential increase of 94.86% [14][16] Investment Recommendation - Butterfly Network is currently rated a Zacks Rank 2 (Buy), presenting a more compelling investment case compared to Tempus AI, which holds a Zacks Rank 3 (Hold), due to its improving financials and lower valuation [18]

Company Overview - DBV Technologies S.A. (DBVT) is a notable stock within the Medical sector, which consists of 999 companies and currently ranks 4 in the Zacks Sector Rank [2] - The company is categorized under the Medical - Biomedical and Genetics industry, which includes 506 stocks and is ranked 70 in the Zacks Industry Rank [6] Performance Metrics - DBVT has experienced a year-to-date gain of approximately 210.7%, significantly outperforming the average loss of 4.4% in the Medical sector [4] - The Zacks Consensus Estimate for DBVT's full-year earnings has increased by 78.9% over the past quarter, indicating a positive shift in analyst sentiment [4] Comparison with Peers - Hims & Hers Health, Inc. (HIMS) is another Medical stock that has shown strong performance, with a year-to-date return of 153.1% and a Zacks Rank of 2 (Buy) [5] - The Medical Info Systems industry, to which HIMS belongs, has seen a year-to-date increase of 16.9%, contrasting with the performance of DBVT's industry [7]

Company Performance - P3 Health Partners Inc. reported a quarterly loss of $6.28 per share, which was worse than the Zacks Consensus Estimate of a loss of $5, and an improvement from a loss of $8 per share a year ago, indicating a surprise of -25.60% [1] - The company posted revenues of $373.23 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 2.61%, but down from $388.49 million in the same quarter last year [2] - P3 Health Partners has not surpassed consensus EPS estimates over the last four quarters, and its shares have lost about 27.3% since the beginning of the year [3][4] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$4 on revenues of $349.3 million, and for the current fiscal year, it is -$18 on revenues of $1.41 billion [7] - The estimate revisions trend for P3 Health Partners is currently favorable, leading to a Zacks Rank 2 (Buy) for the stock, suggesting it is expected to outperform the market in the near future [6] Industry Context - The Medical Info Systems industry, to which P3 Health Partners belongs, is currently in the top 20% of over 250 Zacks industries, indicating a positive outlook for stocks within this sector [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor decisions [5]

Core Viewpoint - Tempus AI has shown significant growth and investor interest following its IPO, with a year-to-date stock increase of 91.8%, outperforming the Medical Info Systems industry and the broader market [1][2]. Financial Performance - In Q1 2025, Tempus AI reported a 75.4% year-over-year revenue increase and a 99.8% rise in gross profit [6]. - Genomics revenues grew by 89% year over year, with the core clinical diagnostics business expanding by 31% due to a 20% increase in volume [7]. - The company reported an adjusted EBITDA loss of $16.2 million, an improvement from a $43.9 million loss in the same period last year [8]. Strategic Partnerships and Initiatives - Tempus AI secured a $200 million, three-year deal with AstraZeneca and Pathos to develop a large oncology foundation model, increasing its total remaining contract value to over $1 billion [9]. - The acquisition of Ambry Genetics and the launch of the "olivia" personal health concierge app have enhanced the company's capabilities [10]. Revenue Guidance and Market Outlook - The company raised its full-year 2025 revenue outlook to $1.25 billion, indicating an 80% year-over-year growth, and expects a positive adjusted EBITDA of $5 million for the year [11]. - The recent executive order aimed at reducing U.S. drug prices could benefit Tempus AI by increasing demand for its AI-driven diagnostics and real-world data tools [12]. Valuation and Market Position - Despite recent gains, Tempus AI's stock is still 29.2% below its 52-week high, suggesting potential for further upward movement [13]. - The stock is currently trading at a forward price-to-sales ratio of 8.21, which is above the industry average of 6.0, indicating it may be slightly overvalued [14]. Investment Recommendation - Tempus AI is viewed as a "Hold" for now, with strong long-term potential but facing competition and currently trading at a premium [16].

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.While many investors like to look for moment ...

分组1 - Nyxoah SA reported a quarterly loss of $0.63 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.49, and compared to a loss of $0.45 per share a year ago, indicating an earnings surprise of -28.57% [1] - The company posted revenues of $1.12 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 29.71%, and this was a decline from year-ago revenues of $1.33 million [2] - Nyxoah shares have decreased by approximately 27.8% since the beginning of the year, contrasting with the S&P 500's gain of 0.1% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is -$0.54 on revenues of $2.12 million, and for the current fiscal year, it is -$2.25 on revenues of $15.16 million [7] - The Medical Info Systems industry, to which Nyxoah belongs, is currently ranked in the top 20% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]